Phosphorus intros PhosphorusONE test
Phosphorus, a leader in diagnostic and bioinformatic solutions for clinical next generation sequencing is launching its PhosphorusONE test.
The product offers an assessment of genetic health meant for identifying and preventing risk for genetic conditions.
The healthy screen analyzes 375 genes covering 170 inherited conditions and 175 different drug reactions. It provides information on a person’s genetic health risk for certain disease, such as cancer, heart disease, dementia, and vision loss. It also assesses a person’s predisposition to adverse reaction to drugs and therapeutics, and assesses certain wellness traits, according to the company.
“We are very excited to have received approval from New York State for PhosphorusONE,” said Alex Bisignano, Phosphorus’ CEO. “This is the only test of its kind that has earned NYSDOH approval and as such we feel honored to enable New York state residents to gain access to it. PhosphorusONE will provide valuable information about an individual’s health profile at an affordable price. We take great pride in delivering excellent quality in everything we do at Phosphorus from our lab results to our software to our customer support. The New York State Department of Health demands that companies meet a high standard of quality in testing and rigor in process, and we are pleased to earn their approval to offer this comprehensive, valuable test.”
No comments found